AR078114A1 - Derivados de cromona, procesos para su preparacion y aplicaciones terapeuticas de los mismos - Google Patents
Derivados de cromona, procesos para su preparacion y aplicaciones terapeuticas de los mismosInfo
- Publication number
- AR078114A1 AR078114A1 ARP100103170A ARP100103170A AR078114A1 AR 078114 A1 AR078114 A1 AR 078114A1 AR P100103170 A ARP100103170 A AR P100103170A AR P100103170 A ARP100103170 A AR P100103170A AR 078114 A1 AR078114 A1 AR 078114A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydrogen atom
- atom
- alkoxy
- Prior art date
Links
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical class [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000005606 carbostyryl group Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000004777 chromones Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005309 thioalkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente se refiere a derivados de cromona, su preparacion, sus composiciones farmacéuticas y su aplicacion como ligandos dopaminérgicos de D3 en carácter de medicamentos para desordenes del sistema nervioso central. Reivindicacion 1: Un compuesto de la formula general 1 caracterizado porque: R1 representa uno o más sustituyente/s idéntico/s o diferente/s en el anillo de benceno, cada uno representa, independientemente, un átomo de hidrogeno o un átomo halogeno, o un grupo C1-4 alcoxi o un grupo OH, o un grupo C1-4 alquilo o un grupo -O(CH2)O- en el cual n = 1 o 2. R2 representa un átomo de hidrogeno o un grupo a C1-4 alquilo, A y B representan, independientemente, un átomo de nitrogeno o un átomo de carbono, R3 representa un átomo de hidrogeno o uno o más sustituyente/s idéntico/s o diferente/s seleccionados del grupo integrado por: un átomo halogeno, un grupo a alquilo C1-4, a alcoxi C1-4 o grupo tioalcoxi C1-4, un grupo -O(CH2)O- en el cual n = 1 o 2, un grupo NO2, un grupo NHSO2R4, un grupo NHR5, un grupo OH, un grupo haloalquilo C1-4, un grupo CN, un grupo alcoxicarbonilo C1-4, un grupo alquilcarbonilo C1-4, un grupo hidroxialquilo C1-4 y un sustituyente bencilo o fenilo opcionalmente sustituido por un grupo alcoxi C1-4 o un grupo alquilo C1-4 o un átomo halogeno, o R3 constituye un anillo fusionado con el anillo de benceno que lo porta, seleccionado del grupo integrado por un naftaleno, un indol, un benzimidazol, un carboestirilo, una benzoxazolona y una benzimidazolona, R4 representa un grupo alquilo C1-4 o un grupo dialquilamino C1-4 o un grupo alcoxialquilo C1-4 o un grupo dialquilaminoalquilo C1-4 o un grupo fenilo o un grupo fenil-C1-4 alquilo, R5 representa un átomo de hidrogeno o un grupo alquilcarbonilo C1-4 o un grupo alcoxicarbonilo C1-4, y además sus sales farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0955944A FR2949465B1 (fr) | 2009-09-01 | 2009-09-01 | Derives chromones, leur procede de preparation et leurs applications therapeutiques |
| US33699210P | 2010-01-29 | 2010-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078114A1 true AR078114A1 (es) | 2011-10-12 |
Family
ID=41403421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103170A AR078114A1 (es) | 2009-09-01 | 2010-08-30 | Derivados de cromona, procesos para su preparacion y aplicaciones terapeuticas de los mismos |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8546402B2 (es) |
| EP (1) | EP2470520B1 (es) |
| JP (1) | JP5786229B2 (es) |
| KR (1) | KR101663635B1 (es) |
| CN (1) | CN102482251B (es) |
| AR (1) | AR078114A1 (es) |
| AU (1) | AU2010290871B2 (es) |
| BR (1) | BR112012003741B1 (es) |
| CA (1) | CA2771061C (es) |
| CL (1) | CL2012000516A1 (es) |
| CO (1) | CO6491096A2 (es) |
| DK (1) | DK2470520T3 (es) |
| ES (1) | ES2428751T3 (es) |
| FR (1) | FR2949465B1 (es) |
| GE (1) | GEP20146080B (es) |
| HR (1) | HRP20130832T1 (es) |
| IL (1) | IL217729A (es) |
| MA (1) | MA35674B1 (es) |
| MX (1) | MX2012002543A (es) |
| MY (1) | MY162345A (es) |
| NZ (1) | NZ597930A (es) |
| PL (1) | PL2470520T3 (es) |
| PT (1) | PT2470520E (es) |
| RU (1) | RU2545214C2 (es) |
| SG (1) | SG178198A1 (es) |
| SI (1) | SI2470520T1 (es) |
| TN (1) | TN2012000049A1 (es) |
| TW (1) | TWI510483B (es) |
| UA (1) | UA109260C2 (es) |
| WO (1) | WO2011027289A1 (es) |
| ZA (1) | ZA201200770B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8604049B2 (en) | 2008-08-05 | 2013-12-10 | Boehringer Ingelheim International Gmbh | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
| PE20120509A1 (es) | 2009-05-13 | 2012-05-09 | Gilead Sciences Inc | Derivados 9,9 difluoro-9h-fluoreno que tiene actividad antiviral |
| EA201201052A1 (ru) | 2010-01-29 | 2013-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk |
| JP5860960B2 (ja) | 2011-07-26 | 2016-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キノリン類及び医薬としてのそれらの使用 |
| UA116087C2 (uk) | 2011-09-16 | 2018-02-12 | Гіліад Фармассет Елелсі | Композиція для лікування вірусу гепатиту c |
| MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| SG11201600919UA (en) | 2013-08-27 | 2016-03-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| EP3079688B1 (en) * | 2013-12-13 | 2017-11-22 | Pierre Fabre Médicament | A chromone derivative as a dopamine d3 receptor antagonist for its use in the treatment of autism spectrum disorder |
| MX2020004443A (es) | 2017-11-03 | 2020-11-24 | Pf Medicament | Tratamiento de la esquizofrenia. |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| JP2023539931A (ja) * | 2020-09-09 | 2023-09-20 | オーリジーン オンコロジー リミテッド | Ｃｂｐ／ｅｐ３００ブロモドメイン阻害剤としての複素環式化合物 |
| CN112220782B (zh) * | 2020-11-11 | 2021-08-20 | 中国人民解放军军事科学院军事医学研究院 | 1,2,4-三甲氧基苯在防治创伤后应激障碍中的应用 |
| US12037340B2 (en) | 2021-05-21 | 2024-07-16 | Gilead Sciences, Inc. | Pentacyclic derivatives as Zika virus inhibitors |
| US12497408B2 (en) | 2021-05-21 | 2025-12-16 | Gilead Sciences, Inc. | Tetracyclic compounds and methods for the treatment of Zika virus infection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089497A (en) * | 1990-09-20 | 1992-02-18 | Warner-Lambert Company | Substituted piperazines as central nervous system agents |
| DE4233963A1 (de) * | 1992-10-08 | 1994-04-14 | Schwabe Willmar Gmbh & Co | Neue Benzopyranone, Verfahren zu ihrer Herstellung und Verwendung |
| RU2320656C2 (ru) * | 2002-07-04 | 2008-03-27 | Шварц Фарма Аг | Производные гетероаренкарбоксамида, способ их получения, фармацевтическая композиция на их основе и применение |
| EP1683790A1 (en) * | 2005-01-24 | 2006-07-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands |
| NZ556800A (en) * | 2005-02-18 | 2011-01-28 | Acino Pharma Ag | Novel processes for the preparation of a 2H-chromene (Iclaprim) |
| FR2903986A1 (fr) * | 2006-07-21 | 2008-01-25 | Pierre Fabre Medicament Sa | Nouveaux derives chromenes ou thiochromenes carboxamides, leur procede de preparation et leurs applications en therapeutique |
-
2009
- 2009-09-01 FR FR0955944A patent/FR2949465B1/fr not_active Expired - Fee Related
-
2010
- 2010-08-10 TW TW099126581A patent/TWI510483B/zh not_active IP Right Cessation
- 2010-08-30 AR ARP100103170A patent/AR078114A1/es active IP Right Grant
- 2010-08-31 CA CA2771061A patent/CA2771061C/en active Active
- 2010-08-31 JP JP2012527432A patent/JP5786229B2/ja active Active
- 2010-08-31 RU RU2012106743/04A patent/RU2545214C2/ru active
- 2010-08-31 US US13/393,542 patent/US8546402B2/en not_active Expired - Fee Related
- 2010-08-31 GE GEAP201012642A patent/GEP20146080B/en unknown
- 2010-08-31 WO PCT/IB2010/053895 patent/WO2011027289A1/en not_active Ceased
- 2010-08-31 NZ NZ597930A patent/NZ597930A/xx not_active IP Right Cessation
- 2010-08-31 MY MYPI2012000354A patent/MY162345A/en unknown
- 2010-08-31 BR BR112012003741-2A patent/BR112012003741B1/pt not_active IP Right Cessation
- 2010-08-31 CN CN201080038431.7A patent/CN102482251B/zh not_active Expired - Fee Related
- 2010-08-31 SG SG2012006870A patent/SG178198A1/en unknown
- 2010-08-31 UA UAA201202432A patent/UA109260C2/ru unknown
- 2010-08-31 EP EP10754594.9A patent/EP2470520B1/en active Active
- 2010-08-31 MX MX2012002543A patent/MX2012002543A/es active IP Right Grant
- 2010-08-31 SI SI201030323T patent/SI2470520T1/sl unknown
- 2010-08-31 AU AU2010290871A patent/AU2010290871B2/en not_active Ceased
- 2010-08-31 DK DK10754594.9T patent/DK2470520T3/da active
- 2010-08-31 PL PL10754594T patent/PL2470520T3/pl unknown
- 2010-08-31 ES ES10754594T patent/ES2428751T3/es active Active
- 2010-08-31 HR HRP20130832AT patent/HRP20130832T1/hr unknown
- 2010-08-31 KR KR1020127005385A patent/KR101663635B1/ko not_active Expired - Fee Related
- 2010-08-31 PT PT107545949T patent/PT2470520E/pt unknown
-
2012
- 2012-01-25 IL IL217729A patent/IL217729A/en active IP Right Grant
- 2012-01-27 CO CO12013015A patent/CO6491096A2/es active IP Right Grant
- 2012-01-31 TN TNP2012000049A patent/TN2012000049A1/en unknown
- 2012-01-31 ZA ZA2012/00770A patent/ZA201200770B/en unknown
- 2012-02-09 MA MA34616A patent/MA35674B1/fr unknown
- 2012-02-28 CL CL2012000516A patent/CL2012000516A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078114A1 (es) | Derivados de cromona, procesos para su preparacion y aplicaciones terapeuticas de los mismos | |
| CR10148A (es) | Derivados de las benzamidas y heteroarenos | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
| UY31254A1 (es) | Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones | |
| UY33458A (es) | Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos | |
| PA8814401A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| CO6410298A2 (es) | Pirimidinas fusionadas | |
| CR10243A (es) | "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos" | |
| SV2006002098A (es) | Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a | |
| PE20081559A1 (es) | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA | |
| AR070558A1 (es) | Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. | |
| CU20110078A7 (es) | Compuestos de carbazol | |
| CR20140089A (es) | Nuevos derivados bicíclicos de dihidroquinolina-2-ona | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| GT201400144A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| NI200700270A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| HN2010001563A (es) | Compuestos | |
| CO6300941A2 (es) | Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7 | |
| ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| AR078171A1 (es) | Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas | |
| AR080871A1 (es) | Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa | |
| UY35947A (es) | Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen | |
| UY33722A (es) | Oxazolidinonas como moduladores de mglur5 | |
| AR062013A1 (es) | Derivados cromenos o tiocromenos carboxamidas, su procedimiento de preparacion y sus aplicaciones en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |